Almotriptan dosage and administration: Difference between revisions

Revision as of 01:56, 5 February 2014

Almotriptan
AXERT^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Almotriptan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

Adults and adolescents age 12 to 17 years: 6.25 mg or 12.5 mg single dose; may repeat after 2 hours if headache returns; benefit of second dose in patients who have failed to respond to first dose has not been established; maximum daily dose 25 mg

Patients with hepatic or severe renal impairment: 6.25 mg starting dose; maximum daily dose 12.5 mg

Revision as of 01:41, 5 February 2014 (view source) Pratik Bahekar (talk \| contribs) (Created page with "__NOTOC__ {{Almotriptan}} {{CMG}}; {{AE}} {{PB}} ==Dosage and Administration== ==References== {{Reflist\|2}} Category:AntiMigaraineDrugs Category:Drugs")	Revision as of 01:56, 5 February 2014 (view source) Pratik Bahekar (talk \| contribs) No edit summary Newer edit →
Line 6:	Line 6:


		* Adults and adolescents age 12 to 17 years: 6.25 mg or 12.5 mg single dose; may repeat after 2 hours if headache returns; benefit of second dose in patients who have failed to respond to first dose has not been established; maximum daily dose 25 mg

		* Patients with hepatic or severe renal impairment: 6.25 mg starting dose; maximum daily dose 12.5 mg